Association between fibrinogen/albumin ratio and severity of coronary artery calcification in patients with chronic kidney disease: a retrospective study

Yuyu Zhu[1], Shuman Tao[1], Danfeng Zhang[1], Jianping Xiao[1], Xuerong Wang[1], Liang Yuan[1], Haifeng Pan[2], Deguang Wang[1]

[1] Department of Nephrology, The Second Affiliated Hospital of Anhui Medical University, Hehei, Anhui Province, China
[2] School of Public Health of Anhui Medical University, Hehei, Anhui Province, China

Corresponding Author:
Deguang Wang[1]
Department of Nephrology, The Second Affiliated Hospital of Anhui Medical University, Hehei, Anhui Province, China
wangdeguang@ahmu.edu.cn

Abstract

Aim: Previous studies have shown that the fibrinogen to albumin ratio (FAR) is closely related to the severity and prognosis of coronary atherosclerosis. In this study, we sought to evaluate the association between FAR and the degree of coronary artery calcification (CAC) in patients with chronic kidney disease (CKD).

Methods: In this retrospective study, 218 patients with CKD were stratified into low, medium and high FAR groups according to the tertiles of the FAR values. The CAC scores, clinical information and laboratory test results of the three FAR groups were compared. To explore the relationship between FAR and CAC we conducted binary logistic regression and correlation analyses.

Results: In the low FAR group, the CAC scores were significantly lower than those in the medium and high FAR groups (P<0.001). There was a significant correlation between the FAR and CAC scores (r=0.510, P<0.001). The FAR was an independent predictor of CAC (OR=1.202, P=0.004).

Conclusion: In patients with CKD, the FAR can be considered as an effective predictor of CAC.

Key words fibrinogen/albumin ratio; coronary artery calcification; chronic kidney disease

Introduction

Chronic kidney disease (CKD) is a widespread disease among the many chronic diseases that inflict great harm upon the world population. The incidence of CKD in China has reached 10.8% and is still on the rise (Sun et al., 2020), and has become a critical public health concern. Most CKD patients eventually die from cardiovascular- and cerebrovascular-related complications due to the high mortality rate caused by coronary artery calcification (CAC) (Turakhia et al., 2018; Bundy et al., 2019). Vascular calcification (VC) occurs in the early stages of CKD and gradually worsens as the disease progresses. VC results in thickening and stiffness of the muscularis layer of the arterial wall, and is primarily caused by calcification at the intima and media layers. Medial calcification is more common in CKD and is often referred to as simply VC. Unlike atherosclerosis, medial calcification is the result of intramembranous ossification, which is similar to osteogenesis and is mainly regulated by vascular smooth muscle cells (VSMCs). (Ottolini & Sonkusare, 2021). During calcification, VSMCs proliferate at an increased rate, decrease contractile protein expression, and gradually transdifferentiate into an osteoblastic/chondrocyte phenotype that releases matrix vesicles (Chen, Zhou & Yang, 2021). When high phosphorus levels are present, differentiation of

Commented [SE1]: The introductory statements need to be reviewed for acccuray

Commented [SE2]: This is not the case. Causality is unproven and it is certainly not due exclusively to CAC.

Commented [SE3]: This is not accurate. Where is the evidence the intimal VC results in arterial stiffness?

Commented [SE4]: Suggest delete this sentence

Commented [SE5]: This is not true. True ossification is a very rare event and certainly not the only mechanism of VC

Commented [SE6]: Actually they become synthetic and senescent

Commented [SE7]: This is one of several mechanisms of VC

Commented [SE8]: Phosphate not phosphorus throughout

VSMCs into a bone/chondrogenic phenotype can occur (Voelkl et al., 2018). In the clinical course of CKD patients, in addition to high levels of phosphorus and parathyroid hormone, other factors that promote VC include oxidative stress and inflammation.

Coagulopathy is a common symptom of CKD patients. Clot formation is delayed, but at the same time there is a slower rate of clot decomposition and increased clot strength. Fibrinogen is a glycoprotein produced and secreted by the liver that eventually distributes to the serum. CKD leads to increased fibrinogen levels in the body, which ultimately mediates the increased clot strength (Nunns et al., 2017).

Many other studies have shown that hypoalbuminemia is closely related to CKD. Several recent studies have reported the relationship between cardiovascular disease (CVD) and the fibrinogen/albumin ratio (FAR), confirming the relationship between CVD and FAR, a marker of systemic inflammation. In addition, FAR has important prognostic value in the assessment of end-stage renal disease (Zou et al., 2020) and acute coronary syndrome (Çetin et al., 2020). Among them, Zou et al. (2020) believe that FAR can be used as a key indicator to provide a predictive program for peritoneal dialysis all-cause mortality and CVD mortality in assessing the prognosis of patients with end-stage renal disease. Studies related to coronary heart disease have found that contrast-induced nephropathy after carotid angiography is generally associated with patients who have high FAR values (Ertas, Avci & Kiris, 2019). In patients with stable coronary heart disease, high FAR values are also associated with the formation of coronary artery side branch circulation (Zhao et al., 2020). After a comprehensive consideration of the medical literature, we aimed to retrospectively study possible correlations between FAR and CAC in CKD patients.

Materials and Methods

Patients

We obtained clinical data from 366 CKD patients who had been admitted during October 2018 to December 2020 to The Second Affiliated Hospital of Anhui Medical University (Hehei, Anhui Province, China).

The inclusion criteria for the study were: (1) ages over 18 years, (2) diagnosis of chronic nephritis, and (3) availability of complete clinical and laboratory data. The exclusion criteria for the study were presence of: (1) blood diseases, which may cause abnormal fibrinogen, (2) active infections, (3) malignant tumors or autoimmune diseases, and (4) history of taking anticoagulants during the past three months.

In this study, 274 CKD patients were screened. This study was approved in advance by the ethics committee of The Second Affiliated Hospital of Anhui Medical University (authorization number YJ-YX2017-004.) All patients signed an informed consent form before data collection. The data were kept anonymous and confidential, and the survey results were used only for scientific research.

Data collection

Venous blood samples were obtained from all patients before treatment and were sent for laboratory analysis within 3 h of collection. Levels of the following laboratory parameters were measured in the samples: fibrinogen (FIB), albumin (ALB), uric acid (UA), calcium, creatinine, phosphorus, alkaline phosphatase, high-sensitivity C-reactive protein (hs-CRP), parathyroid hormone (PTH), procalcitonin (PCT), serum glucose, total cholesterol (TC), 25-dihydroxyvitamin D (25(OH)D), triglycerides, urea nitrogen, high-density lipoprotein cholesterol (HDL-C), glycated hemoglobin and low-density lipoprotein cholesterol (LDL-C). To determine other factors, the following calculations were made: calcium correction=serum

calcium+0.02×(40-ALB); PLR=absolute platelet count/absolute lymphocyte count; NLR=absolute neutrophil count/absolute lymphocyte count and FAR=fibrinogen/albumin.

CAC score

Non-enhanced multislice coronary computed tomography (Philips iCT Brilliance 256, Koninklijke Philips N.V., Amsterdam, Netherlands) was performed at baseline. A radiologist read all CT scans. Next, the pseudo-continuous variable Agatston score was calculated, which is related to the area of the basal coronary artery and the plaque density. Calcification was defined as a CT value >130 HU, with calcification area >1 mm^2. The calcification score was calculated as the calcification area × peak calcification, with 1 point: 130-199 HU, 2 points: 200-299 HU, 3 points: 300-399 HU and 4 points: >400 HU. The total CAC score was the sum of the VC scores of the left main, left anterior descending, right main and supination branches of the coronary arteries. Patients were stratified according to their CAC scores into the calcification group (CAC score >0 HU) and non-calcification group (CAC score = 0 HU).

Statistical analysis

All anonymous data were recorded in an EpiData database (EpiData Association, Odense, Denmark). SPSS 23.0 software (IBM Corporation, Armonk, NY, USA) was used for statistical analysis. For continuous variables, normally distributed data is represented by the mean and standard deviation, and non-normally distributed data by the median, first quartile and third quartile. Tukey's analysis (*F*) or non-parametric analysis (H) was used to test the differences among the three FAR groups. Percentages and frequencies were used to characterize categorical variables. The chi-square (χ^2) test was applied for comparisons of different categorical variable groups, and Bonferroni correction was used to further analyze

Commented [SE9]: Please add in the descriptions of the ANOVA and post hoc tests for multiple comparisons that were used.

Commented [SE10]: Specifically which tests were used for the non-parametric analysis?

the differences in each category. Exploration of the relationship between CAC and FAR was based on binary logistic regression analysis (odds ratio: OR) and Spearman correlation analysis (correlation coefficient: *r*). *P*<0.05 was considered statistically significant.

Commented [SE11]: Describe in greater detail how the univariate and multivariate regression was performed

Commented [SE12]: 2-tailed?

Results

Patient characteristics

The total number of patients with CKD included in this study was 218, of which 127 were men. The mean age of all patients was 53.0±14.6 years. We did not detect any contrast-induced nephropathy in non-hemodialysis patients.

Patients were classified into three groups according to the tertiles of the FAR value, as follows: FAR≤0.079 was the low FAR group (n=73 patients), 0.079<FAR≤0.102 was the medium FAR group (n=71 patients) and FAR>0.102 was the high FAR group (n=74 patients). As shown in Table 1, patient characteristics and demographic variables are presented for the three FAR groups. There were no significant differences in gender, body mass index, smoking, drinking, primary disease, dialysis modality or hypertension among the low, middle and high FAR groups (*P*>0.05). The percentages of patients who took different medications (levocarnitine injection, recombinant human erythropoietin injection, three classes of antihypertensive agents) were not significantly different (*P*>0.05). However, patients in the high FAR group had a higher prevalence of diabetes (*P*=0.008) and were older (*P*<0.001). The middle FAR group had the highest rate of insulin usage (*P*=0.003).

Commented [SE13]: How was this tested?

Commented [SE14]: What about medications that impact mineral metabolism? Intestinal phosphate binders, nutritional/active vitamin D, calcimimetics etc?

Table 1:

Relationship between patient characteristics and fibrinogen/albumin ratio.

Characteristic	Low FAR[a]	Middle FAR[a]	High FAR[a]	F/χ^2 value	*P* value
Age (years, mean±SD)	47.38±13.70	53.76±12.57*	58.86±13.17*#	14.034	<0.001
Gender (male), n (%)	48 (65.8)	38 (53.5)	41 (55.4)	2.589	0.274
BMI (kg/m^2, mean±SD)	22.56±3.56	23.16±3.27	23.85±3.86	2.355	0.097
Smoking, n (%)	22 (30.1)	21 (29.6)	16 (21.6)	1.687	0.430
Drinking, n (%)	13 (17.8)	8 (11.3)	13 (17.6)	1.500	0.472
Primary disease, n (%)				2.625	0.269
Chronic glomerulonephritis	29 (39.7)	24 (33.8)	39 (52.7)		
Chronic nephrotic syndrome	26 (35.6)	23 (32.4)	10 (13.5)		
Hypertensive nephropathy	4 (5.5)	4 (5.6)	8 (10.8)		
Diabetic nephropathy	2 (2.7)	11 (15.5)	10 (13.5)		
Other[b]	12 (16.4)	9 (12.7)	7 (9.5)		
CKD stage, n (%)				2.142	0.343
3	14 (19.2)	4 (5.6)	4 (5.4)		
4	2 (2.7)	3 (4.2)	2 (2.7)		
5	11 (15.1)	14 (19.7)	18 (24.3)		
5d	16 (63.0)	50 (70.4)	50 (67.6)		
Dialysis modality, n (%)				5.224	0.073
No dialysis	27 (37.0)	21 (29.6)	24 (32.4)		
Hemodialysis	42 (57.5)	37 (52.1)	29 (39.2)		
Peritoneal dialysis	4 (5.5)	13 (18.3)	11 (28.4)		
Hypertension, n (%)	51 (69.9)	54 (76.1)	54 (73.0)	0.699	0.705
Diabetes mellitus, n (%)	5 (6.8)	15 (21.1)*	19 (25.7)*	9.718	0.008
Anti-hypertensive agent, n (%)					
Calcium channel blocker	42 (57.5)	46 (64.8)	44 (59.5)	0.849	0.654
β-blocker	24 (32.9)	20 (28.2)	22 (29.7)	0.394	0.821
Angiotensin-aldosterone antagonists	21 (28.8)	17 (23.9)	19 (25.7)	0.447	0.800

Commented [SE15]: This is not required

Insulin, n (%)	2 (2.7)	13 (18.3)*	12 (16.2)*	11.763	0.003
Recombinant human erythropoietin injection, n (%)	41 (56.2)	45 (63.4)	43 (58.1)	0.828	0.661
Levocarnitine injection, n (%)	37 (50.7)	31(43.7)	24 (32.4)	6.745	0.150

BMI: body mass index; CKD: chronic kidney disease; *F*: statistics of Tukey's analysis; χ^2: statistics of chi-square test; SD: standard deviation.

[a] Low FAR group (n=73): FAR≤0.079; medium FAR group (n=71): 0.079<FAR≤0.102; high FAR group (n=74): FAR>0.102.

[b] Other primary disease includes lupus nephritis, polycystic kidney disease and IgA nephropathy.

*: compared with low FAR group, *P*<0.05; #: compared with middle FAR group, *P*<0.05

Commented [SE16]: Please provide more details of how this was performed. Presumably this is the post hoc test for multiple comparisons? This is not an F test.

Laboratory parameters

As shown in Table 2, higher levels of urea nitrogen (*F*=3.351, *P*=0.037), serum glucose (*H*=7.463, *P*=0.024), hs-CRP (*H*=16.546, *P*<0.001), PCT (*H*=6.826, *P*=0.033), NLR (*H*=16.697, *P*<0.001), PLR (*H*=9.189, *P*=0.010) and CAC score (*H*=18.908, *P*<0.001) were found in the high FAR group. The middle FAR group had a slightly higher alkaline phosphatase level (*P*<0.001). Analysis of the results showed that the urea nitrogen level in the low FAR group was much lower than that in the high FAR group or the medium FAR group (*P*=0.004). In addition, the 25(OH)D level in the low FAR group was much higher than that in the high FAR group or the medium FAR group (*P*<0.001). Levels of other parameters including hemoglobin, glycated hemoglobin, total cholesterol, triglycerides, HDL-C, LDL-C, phosphorus, calcium, creatinine, uric acid, PTH, AST and ALT were not significantly different among the three FAR groups (*P*>0.05).

Commented [SE17]: F & H statistics do not need to be reported.

Table 2:

Correlations between laboratory parameters and fibrinogen/albumin ratio.

Parameter	Low FAR[a]	Middle FAR[a]	High FAR[a]	*F*/H value	*P* value
Urea nitrogen (μmol/L)[b]	16.63±7.74	19.64±9.37	20.25±9.62*	3.351	0.037
Alkaline phosphatase (U/L)[c]	83 (66, 117.5)	112.5 (80.50, 193.25)*	104 (79.75, 163)*	15.302	<0.001
Serum glucose (mg/dl)[c]	4.45 (4.19, 4.99)	4.66 (4.19, 5.60)	4.88 (4.25, 5.90)*	7.463	0.024
25(OH)D (ng/dl)[b]	23.21±11.43	18.62±10.34*	15.55±9.87*	7.805	0.001
hs-CRP (mg/L)[c]	0.9 (0.6, 1.85)	2.45 (1.10, 6.00)*	4.50 (1.00, 10.80)*	16.546	<0.001
PCT (ng/ml)[c]	0.12 (0.06, 0.39)	0.15 (0.09, 0.27)	0.31 (0.15, 0.91)	6.826	0.033
NLR[c]	2.66 (2.05, 3.49)	3.20 (2.45, 4.77)*	3.73 (2.65, 5.09)*	16.697	<0.001
PLR[c]	113.89 (88.41, 155.62)	136.67 (103.21, 175.21)	137.64 (112.79, 179.66)*	9.189	0.010
CAC score[c]	0 (0, 31.08)	18.56 (0, 219.50)*	84.87 (0, 395.07)*	18.908	<0.001
CAC, n (%)	29 (39.7)	41 (57.7)	44 (59.5)	5.689	0.017

25(OH)D: 25-dihydroxyvitamin D; CAC: coronary artery calcification; *F:* statistics of Tukey's analysis; H: statistics of non-parametric analysis hs-CRP: high-sensitivity C-reactive protein; NLR: neutrophil/lymphocyte ratio; PCT: procalcitonin; PLR: platelet/lymphocyte ratio.

[a] Low FAR group (n=73): FAR≤0.079; medium FAR group (n=71): 0.079<FAR≤0.102; high FAR group (n=74): FAR>0.102. [b] Mean ± standard deviation. [c] Median (first quartile, third quartile).

*:compared with low FAR group, *P*<0.05; #: compared with middle FAR group, *P*<0.05

Factors related to CAC

Spearman correlation analysis showed that age at dialysis (r=0.210, P=0.028), serum phosphorus (r=0.228, P=0.015), glycated hemoglobin (r=0.340, P=0.049), hs-CRP (r=0.398, P=0.001), PLR (r=0.283, P=0.002), NLR (r=0.256, P=006) and FAR (r=0.510, P<0.001) were positively related to the occurrence of CAC (Table 3).

Commented [SE18]: What about conventional mineral markers; phosphate, calcium, albumin etc?

Commented [SE19]: Not required

Commented [SE20]: Again, as for Table 1, please clarify how this analysis was performed.

Commented [SE21]: Why has this analysis not been applied to all of the continuous variables?

Commented [SE22]: These are not listed in Table 2?

Commented [SE23]: Please clarify whether you are referring to prevalence or severity?

Table 3:

Correlations between laboratory parameters and coronary artery calcification.

Parameter	*r*	*P* value
Age at dialysis	0.210	0.028
Phosphorus	0.228	0.015
Glycated hemoglobin	0.340	0.049
hs-CRP	0.398	0.001
PLR	0.283	0.002
NLR	0.256	0.006
FAR	0.510	<0.001

FAR: fibrinogen/albumin ratio; hs-CRP: high-sensitivity C-reactive protein; NLR: neutrophil/lymphocyte ratio; PLR: platelet/lymphocyte ratio; *r*: Spearman correlation coefficient.

Risk factors for CAC

The dependent variable of the binary logistic regression analysis was whether CAC occurred. Univariate analysis showed that advanced age, CKD stage 5d, hemodialysis, peritoneal dialysis and older age at dialysis, as well as levels of 25(OH)D, PTH, hs-CRP, FAR and uric acid (i.e., decreased) were significantly associated with a higher risk of CAC (P<0.05). Moreover, multivariate analysis demonstrated that age (OR=1.084, *P*<0.001), age at dialysis (OR=1.275, *P*<0.001), PTH (OR=1.001, *P*=0.027), hs-CRP (OR=1.615, *P*=0.023) and FAR (OR=1.202, *P*=0.004) were independent predictors for CAC (Table 4).

Table 4:

Commented [SE24]: Do you mean prevalence?

Commented [SE25]: Please justify why you have entered all of these closely related variables into the model

Commented [SE26]: Why does this not feature in Table 2 or 3?

Commented [SE27]: As per comment for PTH

Commented [SE28]: Please explain this finding

Commented [SE29]: Please report the 95% CI for all Odds ratios

184 **Binary logistic regression analysis of risk factors for coronary artery calcification.**

Factor	Univariate analysis			Multivariate analysis		
	OR	95% *CI*	*P* value	OR	95% *CI*	*P* value
Age	**1.052**	**1.029-1.076**	**<0.001**	**1.084**	**1.053-1.116**	**<0.001**
Gender (ref: female)	1.127	0.658-1.933	0.663			
Smoking (ref: non smoking)	1.625	0.884-2.987	0.118			
BMI	1.076	0.996-1.162	0.063			
CKD stage (ref: stage 3)						
4	3.375	0.532-21.419	0.197			
5	2.667	0.766-9.284	0.123			
5d	**7.445**	**2.396-23.140**	**0.001**			
Dialysis modality (ref: no dialysis)						
Hemodialysis	**4.088**	**2.166-7.715**	**<0.001**			
Peritoneal dialysis	**2.367**	**1.056-5.304**	**0.036**			
Age at dialysis	**1.234**	**1.138-1.339**	**<0.001**	**1.275**	**1.126-1.444**	**<0.001**
Uric acid	**0.997**	**0.995-0.999**	**0.017**			
Creatinine	1.001	1.000-1.002	0.052			
Alkaline phosphatase	1.001	1.000-1.002	0.106			
25(OH)D	**1.030**	**1.001-1.060**	**0.040**			
Phosphorus	1.010	0.637-1.602	0.966			
PTH	**1.001**	**1.000-1.010**	**0.010**	**1.001**	**1.000-1.001**	**0.027**
hs-CRP	**1.073**	**1.006-1.145**	**0.032**	**1.615**	**1.067-3.443**	**0.023**
FAR	**1.161**	**1.058-1.274**	**0.002**	**1.202**	**1.061-1.362**	**0.004**

25(OH)D: 25-dihydroxyvitamin D; BMI: body mass index; CI: confidence interval; CKD: chronic kidney disease; FAR: fibrinogen/albumin ratio; hs-CRP: high-sensitivity C-reactive protein; OR: odds ratio; PTH: parathyroid hormone.

185

Discussion

In our study of CKD patients we found that if the FAR value is higher, the prevalence of CAC is higher. We detected CAC in 54.8% of the total samples. We found that older age and a longer time since beginning dialysis, as well as higher levels of BMI, serum phosphorus, PTH, hs-CRP, NLR and FAR were significantly positively correlated with a higher detection rate of CAC. CKD patients who smoked or had disease stage 5d were more likely to be diagnosed with CAC. Our findings are consistent with those of other researchers. Mizuiri et al. (Mizuiri et al., 2021) showed that many factors significantly affect the probability of CAC in patients undergoing hemodialysis treatment, such as smoking, hs-CRP, diabetes, phosphate levels, gender, time on dialysis, age and blood calcium levels. Chen et al. (Chen, Zhou & Yang, 2021) studied the factors that affect radial artery calcification in patients with end-stage renal disease and found that calcium levels, HbA1c levels, duration of diabetes and duration of dialysis treatment are positively correlated with the degree of radial artery calcification.

FAR and CVD

Several studies have recently explored the relationship between FAR and CVD. Whether patients have ST-elevation myocardial infarction (STEMI) or non STEMI (NSTEMI), FAR can predict SYNTAX scores, and assess severity of cardiovascular diseases and prognosis (Erdoğan et al., 2021; Karahan et al., 2016). In addition, an elevated FAR was significantly associated with no-reflow and short-term mortality in STEMI patients who had primary percutaneous coronary intervention (Xiao et al., 2019; Zhao et al., 2019). The FAR levels were significantly higher in patients with slow coronary blood flow and definitive coronary artery disease (CAD). It is evident that the FAR is very useful for predicting the course of the CAD process (Kayapinar, Ozde & Kaya, 2019). Zou et al. (2020) illustrated that the baseline

Commented [SE30]: Please remove all the subheadings in the discussion apart from limitations and conclusion

FAR was a superior predictor of all-cause and CVD mortality in patients with continuous ambulatory peritoneal dialysis, compared to the established inflammatory markers.

Fibrinogen

Fibrinogen can be viewed as a reactive protein that reflects the acute phase of systemic inflammation, and at the same time it plays an important role in the normal operation of blood coagulation. In the development of inflammation, fibrinogen is conducive to the production of pro-inflammatory cytokines and promotes the development of inflammation (Gobel et al., 2018). The systemic inflammatory response and coagulation are closely related to CKD (Gäckler et al., 2019). At the same time, lymphocytes, monocytes, platelets and endothelial cells will be affected by fibrinogen and its degradation products resulting in changes to the inflammatory response, thereby changing blood flow, causing vascular endothelial damage and thrombosis (Abdul & Sultan, 2019). Enia et al. (Enia et al., 2005) found that death from CVD in peritoneal dialysis patients is independently related to fibrinogen.

Albumin

Albumin is synthesized and secreted by liver cells, which can maintain nutrition and osmotic pressure of the body, transport many insoluble small molecules of organic matter and inorganic ions, and participate in the inflammation process. Serum albumin, as an anti-inflammatory protein, has a protective anti-inflammatory effect during acute inflammation (China et al., 2018). CKD patients lose a large amount of protein in the urine due to renal failure that is often accompanied by hypoalbuminemia. Hypoalbuminemia is an independent risk factor for heart failure and acute coronary syndrome. Moreover, the severity of CAD and

hospital mortality are higher in patients with lower serum albumin (Kumar & Banerjee, 2017).

FAR and CAC

The occurrence of CAC is closely related to the inflammatory response. Fibrinogen and albumin as inflammatory markers may reflect the process of CAC through the following mechanisms. First, pro-inflammatory cytokines such as interleukin-1 will accelerate the synthesis of tumor necrosis factors under the action of fibrinogen. Then, these cytokines act to promote the transformation of VSMCs from the contractile to the bone/chondrogenic phenotype and they eventually become chondrocytes or adulterants (Voelkl et al., 2018). Second, under the action of fibrinogen and metabolites, endothelial function may become damaged, ultimately affecting endothelial cell permeability. Previous studies have shown that the production and progression of CAC are critically affected by vascular endothelial cells. Vascular endothelial cell abnormalities (i.e., abnormal function of morphological changes) due to any cause will promote CAC (Yung et al., 2015). Third, when hypoproteinemia occurs, patients may experience increased oxidative damage and inflammation. At the same time, the presence of cytokines makes it difficult to eliminate oxygen free radicals. For example, interleukin-6 can block the albumin synthesis pathway and elevated TNF-α selectively inhibits albumin gene expression and ultimately reduces the albumin level (Xiao et al., 2019). Finally, when the serum albumin level decreases, the blood becomes more viscous, promoting LDL-C modification to oxidized LDL-C, thereby aggravating VC (Milan et al., 2016; Ding & Manson, 2021).

Inflammation and CKD

The FAR predicts CAC, which may be primarily related to inflammation. Microinflammation is widespread in CKD patients, and is closely related to the increased mortality in dialysis patients (Amdur et al., 2019). The biological incompatibility of the dialysate, abnormal intestinal function, continuous accumulation of toxins produced by uremia and abnormal renal function are closely related to microinflammation. The three factors of VC, oxidative stress and microinflammation influence each other and ultimately increase cardiovascular morbidity and mortality (Schley et al., 2019). Other studies have focused on ratios or evaluation systems to study the relationship between these markers or between the markers and the mortality of CKD patients, such as FAR (Zou et al., 2020), platelet to lymphocyte ratio (PLR) (Duan et al., 2021), neutrophil to lymphocyte ratio (NLR) (Zhang et al., 2021) and Glasgow Outcome Score (GPS) (Cai et al., 2018).

Inflammation and CAC

In our study we found that inflammation markers such as NLR and hs-CRP were related to CAC, which is consistent with the results of previous studies. Li et al. found that the hs-CRP value was positively correlated with VC and believed that the cause was inflammation (Li et al., 2020). Previous studies have shown that excessive CRP causes abnormal endothelial dysfunction. The influence of CRP weakens the activity and expression of endothelial nitric oxide synthase, and the production of nitric oxide is inhibited. In terms of CAC and angiogenesis, nitric oxide plays a key role (Batko et al., 2020). Therefore, when CKD patients have high hs-CRP values, it may be due to a sharp decrease in the amount of nitric oxide and abnormal endothelial function (CRP-mediated). Chandra et al. also

concluded that NLR could be used when predicting VC in end-stage renal disease patients (Chandra et al., 2020). Nam et al. studied Behçet disease patients and believed that CAC and NLR were independently correlated, while CRP, carotid artery intima-media thickness, and NLR were positively correlated (moderate) (Nam, Kang & Song, 2017).

Limitations

Our study has a limitation because the retrospective study design makes it difficult to explain the underlying cause of the relationship between CAC and FAR.

Conclusion

Our study shows that the FAR is positively correlated with CAC. In CKD patients, higher levels of FAR are independently associated with CAC. Moreover, the FAR is a simple, effective, and accurate clinical biomarker that can screen high-risk CAC patients as early as possible and predict the severity of CAC in CKD patients, as well as facilitate accurate clinical decision-making and active follow-up monitoring.

Additional Information and Declarations

Competing Interests

The authors declare there are no competing interests.

Author Contributions

Yuyu Zhu conceived and designed the research, performed the research, analyzed the

Commented [SE31]: This needs to be expanded to consider other pertinent limitations.

Commented [SE32]: Please clarify the meaning of efficacy in this context

Commented [SE33]: You have not assessed diagnostic accuracy

Commented [SE34]: This has not been proven. Your data suggests those with advanced disease on dialysis have higher FAR

Commented [SE35]: It would appear that your modelling looks at prevalence not severity

Commented [SE36]: This needs to be toned down. You haven't presented any evidence to demonstrate that use of FAR achieves more accurate clinical-decision making or monitoring.

data, prepared figures and/or tables, and approved the final draft.

Shuman Tao, Danfeng Zhang, and Haifeng Pan conceived and designed the research, prepared figures and/or tables, and approved the final draft.

Jianping Xiao, Xuerong Wang, and Liang Yuan analyzed the data, authored or reviewed drafts of the paper, reviewed and edited the manuscript, and approved the final draft.

Deguang Wang conceived and designed the research, reviewed drafts of the paper, reviewed and edited the manuscript, and approved the final draft.

Data Availability

The following information was supplied regarding data availability:The data extraction forms (raw data) are available in the Supplemental Files.

Funding

This work was supported by grants from the Natural Science Foundation of Anhui Province (2008085MH244) and Science Foundation of Anhui Medical University (2019xkj140). Refinement and implementation of the study were supported by The Second Affiliated Hospital of Anhui Medical University.

Acknowledgements

We would like to thank all participants in this work.

References

Abdul R M, Sultan A A. 2019. The importance of measurement of plasma fibrinogen level among patients with type- 2 diabetes mellitus. *Diabetes Metab Syndr* 13(2): 1151-1158.

Amdur R L, Feldman H I, Dominic E A, et al. 2019. Use of Measures of Inflammation and Kidney Function for Prediction of Atherosclerotic Vascular Disease Events and Death in Patients With CKD: Findings From the CRIC Study. *Am J Kidney Dis* 73(3): 344-353.

Batko K, Krzanowski M, Pietrzycka A, et al. 2020. Interplay of nitric oxide metabolites and markers of endothelial injury, inflammation, and vascular disease in the spectrum of advanced chronic kidney disease. *Kardiol Pol* 78(1): 51-58.

Bundy J D, Cai X, Scialla J J, et al. 2019. Serum Calcification Propensity and Coronary Artery Calcification Among Patients With CKD: The CRIC (Chronic Renal Insufficiency Cohort) Study. *Am J Kidney Dis* 73(6): 806-814.

Cai L, Yu J, Yu J, et al. 2018. Prognostic value of inflammation-based prognostic scores on outcome in patients undergoing continuous ambulatory peritoneal dialysis. *BMC Nephrol* 19(1): 297.

Çetin M, Erdoğan T, Kırış T, et al. 2020. Predictive value of fibrinogen-to-albumin ratio in acute coronary syndrome. *Herz* 45(S1): 145-151.

Chandra A, Raj G, Awasthi N P, et al. 2020. Evaluation of the relationship between blood cell parameters and vascular calcification in dialysis-dependent end-stage renal disease patients. *Saudi J Kidney Dis Transpl* 31(1): 136-143.

Chen Z, Zhou Y, Yang T. 2021. Histopathological assessment of radial artery calcification in patients with end-stage kidney disease. *Ren Fail* 43(1): 362-370.

348 Chen Z, Zhou Y, Yang T. 2021. Histopathological assessment of radial artery calcification in
349 patients with end-stage kidney disease. *Ren Fail* 43(1): 362-370.
350 China L, Skene S S, Bennett K, et al. 2018. ATTIRE: Albumin To prevenT Infection in chronic
351 liveR failurE: study protocol for an interventional randomised controlled trial. *BMJ Open*
352 8(10): e23754.
353 Ding M, Manson J E. 2021. HDL-c and arterial calcification in midlife women: does an HDL
354 paradox exist? *Menopause* 28(3): 231-233.
355 Duan S, Sun L, Zhang C, et al. 2021. Association of platelet-to-lymphocyte ratio with kidney
356 clinicopathologic features and renal outcomes in patients with diabetic kidney disease. *Int*
357 *Immunopharmacol* 93: 107413.
358 Enia G, Panuccio V, Mallamaci F, et al. 2005. Fibrinogen and calcium x phosphate product are
359 predictors of cardiovascular events in the CAPD population. *J Nephrol* 18(6): 764-769.
360 Ertas F, Avci E, Kiris T. 2019. The Ratio of Fibrinogen to Albumin as a Predictor of Contrast-
361 Induced Nephropathy After Carotid Angiography. *Angiology* 70(5): 458-464.
362 Erdoğan G, Arslan U, Yenercağ M, et al. 2021. Relationship Between the Fibrinogen-to-
363 Albumin Ratio and SYNTAX Score in Patients with Non-St-Elevation Myocardial
364 Infarction. *Rev Invest Clin* 73(7). DOI: 10.24875/RIC.20000534.
365 Gäckler A, Rohn H, Lisman T, et al. 2019. Evaluation of hemostasis in patients with end-stage
366 renal disease. *PLoS One* 14(2): e212237.
367 Gobel K, Eichler S, Wiendl H, et al. 2018. The Coagulation Factors Fibrinogen, Thrombin, and
368 Factor XII in Inflammatory Disorders-A Systematic Review. *Front Immunol* 9: 1731.
369 Karahan O, Acet H, Ertaş F, et al. 2016. The relationship between fibrinogen to albumin ratio

370 and severity of coronary artery disease in patients with STEMI. *Am J Emerg Med* 34(6):
371 1037-42. DOI: 10.1016/j.ajem.2016.03.003.
372 Kayapinar O, Ozde C, Kaya A. 2019. Relationship Between the Reciprocal Change in
373 Inflammation-Related Biomarkers (Fibrinogen-to-Albumin and hsCRP-to-Albumin
374 Ratios) and the Presence and Severity of Coronary Slow Flow. *Clinical and Applied*
375 *Thrombosis/Hemostasis* 25: 1146316850.
376 Kumar D, Banerjee D. 2017. Methods of albumin estimation in clinical biochemistry: Past,
377 present, and future. *Clin Chim Acta* 469: 150-160.
378 Li H, Pan K, Meng Y, et al. 2020. Mutual promotions between periodontitis and vascular
379 calcification by rat animal model. *J Periodontal Res* 55(6): 810-820.
380 Milan M S, Virzi G M, Clementi A, et al. 2016. Pro-inflammatory cytokines: a possible
381 relationship with dialytic adequacy and serum albumin in peritoneal dialysis patients. *Clin*
382 *Kidney J* 9(1): 153-157.
383 Mizuiri S, Nishizawa Y, Doi T, et al. 2021. Iron, coronary artery calcification, and mortality in
384 patients undergoing hemodialysis. *Ren Fail* 43(1): 371-380.
385 Nam S H, Kang S G, Song S W. 2017. The Neutrophil-Lymphocyte Ratio Is Associated with
386 Coronary Artery Calcification in Asymptomatic Korean Males: A Cross-Sectional Study.
387 *Biomed Res Int* 2017: 1989417.
388 Nunns G R, Moore E E, Chapman M P, et al. 2017. The hypercoagulability paradox of chronic
389 kidney disease: The role of fibrinogen. *The American Journal of Surgery* 214(6): 1215-
390 1218.
391 Ottolini M, Sonkusare S K. 2021. The Calcium Signaling Mechanisms in Arterial Smooth

392 Muscle and Endothelial Cells. *Compr Physiol* 11(2): 1831-1869.
393 Schley G, Klanke B, Kalucka J, et al. 2019. Mononuclear phagocytes orchestrate prolyl
394 hydroxylase inhibition-mediated renoprotection in chronic tubulointerstitial nephritis.
395 *Kidney international* 96(2): 378-396.
396 Sun L, Xu H, Wang Y, et al. 2020. The mitochondrial-targeted peptide SBT-20 ameliorates
397 inflammation and oxidative stress in chronic renal failure. *Aging (Albany NY)* 12(18):
398 18238-18250.
399 Turakhia M P, Blankestijn P J, Carrero J J, et al. 2018. Chronic kidney disease and arrhythmias:
400 conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies
401 Conference. *Eur Heart J* 39(24): 2314-2325.
402 Voelkl J, Tuffaha R, Luong T, et al. 2018. Zinc Inhibits Phosphate-Induced Vascular
403 Calcification through TNFAIP3-Mediated Suppression of NF-kappaB. *J Am Soc Nephrol*
404 29(6): 1636-1648.
405 Voelkl J, Tuffaha R, Luong T, et al. 2018. Zinc Inhibits Phosphate-Induced Vascular
406 Calcification through TNFAIP3-Mediated Suppression of NF-kappaB. *J Am Soc Nephrol*
407 29(6): 1636-1648.
408 Xiao L, Jia Y, Wang X, et al. 2019. The impact of preoperative fibrinogen-albumin ratio on
409 mortality in patients with acute ST-segment elevation myocardial infarction undergoing
410 primary percutaneous coronary intervention. *Clin Chim Acta* 493: 8-13. DOI:
411 10.1016/j.cca.2019.02.018.
412 Yung L M, Sanchez-Duffhues G, Ten D P, et al. 2015. Bone morphogenetic protein 6 and
413 oxidized low-density lipoprotein synergistically recruit osteogenic differentiation in

endothelial cells. *Cardiovasc Res* 108(2): 278-287.

Zhao Y, Yang J, Ji Y, et al. 2019. Usefulness of fibrinogen-to-albumin ratio to predict no-reflow and short-term prognosis in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. *Heart Vessels* 34(10): 1600-1607. DOI: 10.1007/s00380-019-01399-w.

Zhang L, Nie Y, Guo M, et al. 2021. Neutrophil to Lymphocyte Ratio as a Predictor of Long-Term Outcome in Peritoneal Dialysis Patients: A 5-Year Cohort Study. *Blood Purif* 1-7.

Zhao Y, Wang S, Yang J, et al. 2020. Association of fibrinogen/albumin ratio and coronary collateral circulation in stable coronary artery disease patients. *Biomark Med* 14(16): 1513-1520.

Zou Y, Zhu Z, Zhou J, et al. 2020. Fibrinogen/Albumin ratio: A more powerful prognostic index for patients with end-stage renal disease. *Eur J Clin Invest* e13266.